EUVIMEDEUVIMED entdecken
Multizentrische Studie

Low-Dose Bevacizumab 0.03 mg for Treatment of Type 1 Retinopathy of Prematurity

Thomas W Hejkal, Shruti Sinha, Pukhraj Rishi, Samiksha F Jain, Paul J Rychwalski

Ophthalmology Retina · 2025-08 · 9 (8) · 807-811

DOI: 10.1016/j.oret.2025.02.009 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Ophthalmology Retina, 2025-08. Verfasst von Thomas W Hejkal und 4 weiteren Autor:innen. Beteiligte Einrichtung: Eye Consultants, Omaha, Nebraska. Hauptthemen laut MEDLINE: Bevacizumab, Retinopathy of Prematurity. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 17 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BevacizumabRetinopathy of PrematurityHumansRetrospective StudiesIntravitreal InjectionsAngiogenesis InhibitorsMaleFemaleInfant, NewbornGestational AgeDose-Response Relationship, DrugTreatment OutcomeFollow-Up StudiesVascular Endothelial Growth Factor ALaser CoagulationInfant, Premature

Stichwörter der Autor:innen

BevacizumabROPRetinopathy of prematurity

Substanzen

BevacizumabAngiogenesis InhibitorsVascular Endothelial Growth Factor A

Autor:innen und Institutionen

  • Eye Consultants, Omaha, Nebraska.
  • Division of Ophthalmology, Children's Hospital and Medical Center, Omaha, Nebraska; Department of Ophthalmology, University of Nebraska Medical Center, Omaha, Nebraska.
  • Department of Ophthalmology, University of Nebraska Medical Center, Omaha, Nebraska.
  • Division of Ophthalmology, Children's Hospital and Medical Center, Omaha, Nebraska; Department of Ophthalmology, University of Nebraska Medical Center, Omaha, Nebraska. Electronic address: prychwalski@childrensnebraska.…

Zitieren

APA

Hejkal, T. W., Sinha, S., Rishi, P., Jain, S. F., & Rychwalski, P. J. (2025). Low-Dose Bevacizumab 0.03 mg for Treatment of Type 1 Retinopathy of Prematurity. Ophthalmology Retina, 9(8), 807-811. https://doi.org/10.1016/j.oret.2025.02.009

Vancouver

Hejkal TW, Sinha S, Rishi P, Jain SF, Rychwalski PJ. Low-Dose Bevacizumab 0.03 mg for Treatment of Type 1 Retinopathy of Prematurity. Ophthalmology Retina. 2025;9(8):807-811. doi:10.1016/j.oret.2025.02.009

BibTeX
@article{Hejkal2025,
  author = {Hejkal, Thomas W and Sinha, Shruti and Rishi, Pukhraj and Jain, Samiksha F and Rychwalski, Paul J},
  title = {Low-Dose Bevacizumab 0.03 mg for Treatment of Type 1 Retinopathy of Prematurity},
  journal = {Ophthalmology Retina},
  year = {2025},
  volume = {9},
  number = {8},
  pages = {807--811},
  doi = {10.1016/j.oret.2025.02.009}
}
Kostenlos starten →